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Background: Epithelial cell adhesion molecule (EpCAM) is overexpressed in solid tumors and regarded as a
putative cancer stem cell marker. Here, we report that employing EpCAM aptamer (EpApt) and EpCAM siRNA (SiEp)
dual approach, for the targeted delivery of siRNA to EpCAM positive cancer cells, efficiently inhibits cancer cell
proliferation.
Results: Targeted delivery of siRNA using polyethyleneimine is one of the efficient methods for gene delivery, and
thus, we developed a novel aptamer-PEI-siRNA nanocomplex for EpCAM targeting. PEI nanocomplex synthesized
with EpCAM aptamer (EpApt) and EpCAM siRNA (SiEp) showed 198 nm diameter sized particles by dynamic light
scattering, spherical shaped particles, of 151 ± 11 nm size by TEM. The surface charge of the nanoparticles was −30.0 mV
using zeta potential measurements. Gel retardation assay confirmed the PEI-EpApt-SiEp nanoparticles formation.
The difference in size observed by DLS and TEM could be due to coating of aptamer and siRNA on PEI nanocore.
Flow cytometry analysis revealed that PEI-EpApt-SiEp has superior binding to cancer cells compared to EpApt or
scramble aptamer (ScrApt) or PEI-ScrApt-SiEp. PEI-EpApt-SiEp downregulated EpCAM and inhibited selectively the
cell proliferation of MCF-7 and WERI-Rb1 cells.
Conclusions: The PEI nanocomplex fabricated with EpApt and siEp was able to target EpCAM tumor cells, deliver
the siRNA and silence the target gene. This nanocomplex exhibited decreased cell proliferation than the scrambled
aptamer loaded nanocomplex in the EpCAM expressing cancer cells and may have potential for EpCAM targeting
in vivo.
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Epithelial cell adhesion molecule (EpCAM) is highly
expressed in most of the solid tumors. It has been re-
ported as a putative cancer stem cell marker [1,2], and is
regarded as a target antigen for cancer therapies using
antibody, ankyrins and aptamers [3,4]. Since an aptamer
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unless otherwise stated.associated with antibody, such as larger size, immuno-
genicity, both DNA and RNA aptamers against EpCAM
were developed using Systemic Evolution of Ligands by
Exponential Algorithm (SELEX) technology, and these
aptamers can be potentially utilized for therapeutic pur-
pose [5,6]. EpCAM RNA aptamer functionalized with
either doxorubicin or SPION-nucleolin aptamers, or bovine
lactoferrin showed greater specificity for cancer cells [7,8].
The EpCAM RNA aptamer was used to deliver curcumin
using PLGA lecithin nanoparticles against colorectal adeno-
carcinoma cells [9].
Even though there are various strategies for targeting
cancer cells, RNA interference (RNAi) is still regarded as
the more suitable approach [10]. RNAi based therapy isentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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munogenicity, easy production and target-specific gene si-
lencing. Clinical trials using siRNA against ribonucleotide
reductase subunit M2 (RRM2) studies show promising re-
sults in humans [11]. Nanocarrier based delivery is gener-
ally preferred due to lack of high penetrance of siRNA
into the cancer cells [12]. In this regard, polymer based
nanocarriers show less immunogenicity, toxicity, and has
better nucleic acid delivery compared to the viral carriers.
Polymeric nanocarrier such as polyethyleneimine [13] is
one of the most explored cationic carriers due to its
high transfection efficiency [14]. However, virosome and
exosome based nanocarriers for the delivery of siRNAs
has also been reported earlier [15-17]. Cell penetrating
peptides and affibodies that can deliver siRNA are as
well reported [18,19]. Among these nanocarriers, PEI
has the best properties for the condensation of nucleic
acids into a nanosized complex. The positively charged
PEI polymer, complexes with negatively charged oligo-
nucleotide through electrostatic interactions and forms
a stable nanocomplex even in the presence of the serum
[20-22]. Also PEI nanocarrier was reported for their
non-mutagenic property and not to induce inflamma-
tory response [23,24].
PEI nanocomplex has been efficiently used for the de-
livery of siRNA using target specific antibody or affibody
or aptamer. When used to deliver, nucleic acid aptamers
(PSMA, Sgc8c and Muc1) fabricated with PEI-siRNA,
target specific delivery to cancer cells was observed
[25-27]. Similarly, the gold nanoparticles fabricated with
SiEp and EpCAM antibody, showed targeted silencing
of EpCAM in the RB cell line [28]. In the present study,
we utilized an aptamer based strategy to deliver siRNA
against EpCAM as a PEI based nanoformulation. The
charge based stabilization of the PEI with the sodium
citrate is found to be more efficient for loading the
siRNA and the aptamer for a targeted delivery [29].
Therefore, we targeted the EpCAM expressing cancer
cells, using an EpCAM aptamer and SiEp loaded PEI
nanocomplex, stabilized with sodium citrate for silen-




Breast cancer cell line (MCF-7) and retinoblastoma cell
line (WERI-Rb1) were obtained from Riken cell bank,
Japan and were grown in DMEM and RPMI 1640
(Sigma-Aldrich, Bangalore, India) supplemented with
10% FBS (fetal bovine serum) (Invitrogen, Bangalore,
India) at 37°C and 5% CO2 humidified atmosphere. 1×
antibiotic and antimycotic solution (Himedia, Mumbai,
India) was added to the complete growth media used
for cell culture.Synthesis and stabilization of PEI: sodium citrate
nanocomplex
PEI stock solution (100 μg/mL) was prepared and the
pH was adjusted to 6.0 using 1 N HCl. The charge ra-
tios of 1:1, 1:1.5, 1:3, 1:5 and 1:7 were prepared be-
tween PEI and sodium citrate based on the amine to
the carboxylic groups present in the complexes [29].
The reaction was incubated for 10 min in a reaction
volume of 1 mL. The size and the zeta-potential of the
nanocomplexes were measured using Zetasizer Nano
ZS (Malvern). The ratio 1:1.5 of PEI to sodium citrate
was used for studying the cytotoxicity in the cell lines,
and also for synthesizing the PEI-EpApt-SiEp and PEI-
ScrApt-SiEp nanocomplex.
Fabrication and characterization of PEI-Aptamer-siRNA
nanocomplex
The PEI concentration (0.3 μg/mL) that was determined
as nontoxic to the cells, was chosen and complexed with
EpCAM Aptamer (EpApt) and EpCAM siRNA (SiEp).
Different concentrations of EpApt (100 nM to 300 nM)
and SiEp (100 nM to 300 nM) were added to the PEI,
and incubated at room temperature for 10 min. The PEI
alone and PEI-Aptamer-siRNA (PEI-Apt-siRNA) nano-
complexes were electrophoresed on 2% agarose gel in
TAE buffer to confirm the complex formation. The size
and zeta potential of the nanocomplex saturated with
aptamer and siRNA were measured using Zetasizer. The
size of PEI nanocomplex was tested in serum supple-
mented and serum free media using zetasizer. TEM was
performed for the PEI-Apt-siRNA nanocomplex (200 nM
EpApt and 200 nM siRNA) and imaged at 80 V (TEM,
Philips, CM12 STEM, Netherlands).
Cellular uptake of the PEI-Aptamer siRNA nanocomplex
Cellular uptake of the PEI-Apt-siRNA nanocomplex was
performed in MCF-7 and WERI-Rb1 cells using flow cy-
tometry (BD Science FACS Caliber). The 200 nM of
aptamer alone or PEI-Apt-siRNA nanocomplex (200 nM
EpApt and 200 nM siRNA) were incubated with 2 × 105
cells for 4 h followed by washing with 1× PBS two times
and the cells were analyzed using BD FACS Calibur.
The unstained cells and the scrambled aptamer treated
cells were included as controls. The uptake of the apta-
mer alone, and PEI-Apt-siRNA nanocomplex was visu-
alized using fluorescent Axio Observer microscopy
(Zeiss, Germany).
Silencing and cytotoxic effect of PEI aptamer-siRNA
nanocomplex on cell culture
The effect of siRNA delivery to the cells was evaluated
using real time PCR or quantitative (qPCR) and Western
blotting. MCF-7 and WERI-Rb1 cells were seeded at a
density of 2 × 105 cells per well of 6 well plate. After
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complexes or lipofectamine-SiEp were added to the
cells in serum deprived media and incubated further for
4 h, followed by the addition of serum containing media.
The nanocomplex treated cells were incubated for 48 h
to study the specific delivery of the EpCAM siRNA to
the targeted cells. The total RNA from treated cells was
extracted using Tri reagent (Sigma, Bangalore, India)
and the cDNA was synthesized using Verso cDNA syn-
thesis kit. The levels of EpCAM mRNA expression
were measured in MCF-7 and WERI-Rb1 cell lines
using TaqMan real time PCR reagents (Applied biosys-
tems, Foster city, USA) using GAPDH expression as an
internal control. The immunoblot analysis was per-
formed to check the EpCAM protein expression in
both cell lines treated with the PEI-Apt-siRNA nano-
complexes or lipofectamine-SiEp. For studying cyto-
toxic effect of these complexes, 7,500 cells per well in
96 well plate were seeded, and treated as per the details
provided in the Additional file 1.
Statistical analysis
Statistical analysis was performed using unpaired student
t-test for all experiments, except for the cell viability
assay, analysis of variance (one-way) is performed and
data interpreted. The results are mean of three independ-
ent experiments. Each experiment consisted of 3 replicates
and was performed atleast twice or thrice. P values less
than 0.001 were considered very significant and indicated
with “**” and P ≤ 0.05 is considered as significant and indi-
cated with “*”.Figure 1 Schematic showing the cell specific silencing strategy media
PEI nanoparticle is formed using sodium citrate as charge stabilizer, followed
complex. This complex guided by the aptamer, binds to the EpCAM positive
silencing and inhibition of cellular function pertained to it.Results
Synthesis and characterization of PEI nanocomplex with
EpCAM Aptamer and siRNA
We have synthesized PEI nanocore and PEI-Apt-SiEp
nanocomplex as shown in schematic representation
(Figure 1). The illustration describes the process of PEI
nanocomplex synthesis followed by siRNA and aptamer
addition. We tested the hypothesis that the nanocom-
plex when added to cells, would specifically bind to the
EpCAM receptor on the membrane, and would release
the aptamers, and siRNA into the cytoplasm, leading to
the silencing of EpCAM mRNA. PEI nanocore was pre-
pared by stabilizing its charge using sodium citrate to
form an optimal core in aqueous solution. The size of
the PEI nanocore depended on the ratios of citrate to
PEI i.e., carboxyl group charge/amine group charge ratio
(R). The PEI: citrate nanocore synthesized with different
R ratios showed particles sizes ranging from 75–250 nm
and zeta-potential ranging from 34 mV to 48 mV (posi-
tively charged). The ratio 1:1.5 of PEI: citrate resulted in
optimum size of 156 ± 6.8 nm and zeta potential of
34.6 mV (Figure 2A & B). The nanocomplex formation
was mediated by stabilization of the positively-charged
PEI by negatively charged sodium citrate, and further by
the electrostatic interaction between the nanocore, the
siRNA and the aptamer. The PEI-Apt-siRNA nanocom-
plexes were synthesized in aqueous media with varying
amounts of the aptamer and siRNA. To the PEI nano-
core, siRNA was added first followed by aptamer. The
aptamer was added finally to form the complex as it
enables the complex to recognize the EpCAM on theted by PEI nanocomplex fabricated with aptamer and siRNA.
by the addition of siRNA and EpCAM aptamer to form the PEI-Apt-siRNA
cells and delivers the siRNA in the cytoplasm resulting in target gene
Figure 2 Effect of citrate on the nanocomplex size, charge and characterization of the nanocomplex. Graph showing the hydrodynamic
sizes (A) and surface charge (B) of PEI: citrate nanocomplexes formed using different ratio of PEI to citrate measured using zetasizer. C. Titration
of different concentration of aptamer and siRNA was carried out and loaded onto 2% agarose gel with ethidium bromide and checked for the
retention of the PEI complex on the wells. Lane 3 shows 200nM of aptamer and 200nM of siRNA is required to saturate 0.3μgs of PEI and the
next highest concentration of 300nM of aptamer & siRNA respectively had some amount of free siRNA and aptamer (lane 4). Lane 5 & 6 indicates
free aptamer and siRNA indicated with red and black arrow respectively. On the right, histogram plot showing Particle size distribution of the
PEI-Apt-siRNA nanocomplex. D. Histogram overlay plot showing the percent number distribution of the PEI nanocore alone and PEI-nanocomplex
with aptamer and siRNA (hydrodynamic diameter in nm) measured using zetasizer. E. Graph showing the total counts of representative zeta-potential
(mV) of the PEI nanocore and the PEI-Apt-siEp nanocomplex. F. TEM images of the PEI nanocomplex left panel showing the uniformity of particle
distribution and histogram showing distinct particles with a spherical shape (G). H. Graph showing the percentage cell proliferation upon treating with
different concentration from 0.1 to 3 μg/mL of PEI on MCF-7 and WERI-Rb1 cell line till 48 h. Inhibitory effect of PEI on the cell proliferation and
mitrochondrial activity was assessed by MTT assay.
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together would lead to a lesser occupancy of aptamer on
the particle surface thereby leading to lower binding effi-
ciency of the particles; hence the stepwise complex for-
mation was maintained. The synthesized complexes
exhibited retardation on an agarose gel (Figure 2C). We
observed that 200 nM of aptamer and siRNA, were able
to saturate the PEI: citrate nanocore beyond which free
aptamer and siRNA were present, in addition to that the
complex retained in the well (Figure 2C, lane 4). There-
fore, 200 nM of EpApt and 200 nM SiEp complexed
with PEI-citrate (PEI-EpApt-SiEp) nanocomplex was
used for further studies. This nanocomplex exhibited a
hydrodynamic diameter of 198 ± 14.2 nm and zeta po-
tential of −30.0 mV. The percent number distribution of
the sizes of PEI nanocore alone and nanocomplex are
shown in Figure 2D. Figure 2E shows the zeta potential
of the PEI nanocore alone and nanocomplex, respect-
ively. There was a complete shift in the surface charge
(34.6mV) due to the aptamer and siRNA addition lead-
ing to negative surface charge(−30.0). The TEM analysis
exhibited a particle size of 151 ± 11 nm. The TEM ana-
lysis of both PEI and PEI-Apt-siRNA nanocomplexes
showed spherical particles (Figure 2F). The frequency of
sizes of the particles as observed by TEM is shown as
histogram (Figure 2G).
For the future in vivo applications, we additionally
studied the effect of serum on the size and the charge of
the PEI nanoparticles prepared in aqueous media. For
this, we added the prepared complexes to the RPMI
media with and without the serum. The size of the
nanocomplex in media with and without serum are plot-
ted as overlay percent number distribution and exhibited
very minimal difference (Additional file 2: Figure S1A)
and the charge of the nanocomplex incubated in media
with and without serum showed minor changes were found
to be -18 mV and −18.7 mV respectively (Additional file 2:
Figure S1B & C).
Cytotoxic effect of PEI polymer on cells
MCF-7 and WERI-Rb1 were used to study the cytotoxic
effect of the PEI on cells. The cytotoxicity of PEI was
found to be lesser with decreasing concentration of the
PEI i.e., 3 μg/mL concentration showed higher toxicity,
0.3 μg/mL and 0.1 μg/mL showed lesser cytotoxicity,
hence 0.3 μg/mL was chosen to rule out any non-specific
cellular effects that can be attributed by PEI (Figure 2E).
Therefore, PEI nanocomplexes for the aptamer and the
siRNA functionalization were carried out with the con-
centration of 0.3 μg/mL of PEI.
Cellular uptake of PEI Aptamer siRNA complex
The cell binding and uptake of the PEI-EpApt-SiEp com-
plex were studied in MCF-7 and WERI-Rb1 cell lines.Initially, we studied the expression of EpCAM in retino-
blastoma and the data generated by us in WERI-Rb1 cell
lines is represented in Additional file 2: Figure S1A, [8].
Similarly the expression of EpCAM in MCF-7 has also
been studied earlier [2], and the binding of EpCAM
aptamer to breast cancer cells, MCF-7 cell line is pub-
lished [5]. The expression levels of EpCAM proteins in
MCF-7 cells are higher compared to the WERI-Rb1 cells
(Figure 3A). Similar to the expression levels of the protein,
the aptamer binding was higher in MCF-7(Figure 3B).
The uptake of aptamer and PEI-Apt-SiEp nanocomplexes
was monitored using flow cytometry and the cells bound
to PEI-EpApt-SiEp had increased fluorescent intensity
compared to the cells bound with EpApt alone in both
MCF-7 and WERI-Rb1 cell lines (Figure 3C and D). The
ScrApt or PEI-ScrApt-SiEp did not show any binding onto
the cell lines. The blocking of the cell surface EpCAM
protein by the EpCAM antibody had decreased the bind-
ing of EpCAM aptamer alone or PEI-EpApt-SiEp (Figure 3E
& F). The cellular uptake of the aptamer alone or the
aptamer nanocomplex in MCF-7 and WERI-Rb1 cells
was visualized using fluorescent microscopy. The PEI
nanocomplex on MCF-7 and WERI-Rb1 cells showed
intense membrane staining compared to the EpApt
alone (Figure 4). The PEI-EpApt-siRNA nanocomplex
exhibited greater binding than EpApt alone (Figure 4B
and D). There was no binding when ScrApt or ScrApt-
nanocomplex was used in both the cell lines (Figure 4C,
E upper panel and 4C, E lower panel). Thus, the specifi-
city of the EpCAM aptamer towards the target is in
agreement with the above data.
Silencing efficiency of the nanocomplex
The EpCAM silencing by PEI-EpApt-SiEp nanocomplex
on both MCF-7 and WERI-Rb1 cells were studied by
monitoring the mRNA and protein level using qPCR
and Western blotting, respectively. The PEI-Apt-siRNA
nanocomplex was effective in silencing the EpCAM
compared to the native siRNA transfected using lipofec-
tamine 2000 (Figure 5A). The EpCAM gene was down-
regulated about 56 and 62% in SiEp treated MCF-7 and
WERI-Rb1 cells, while the treatment with PEI-EpApt-
SiEp resulted in significant (P value > 0.05) higher levels
of downregulation of about 64 and 72% in MCF-7 and
WERI-Rb1, respectively. The downregulation was higher
in WERI-Rb1 compared to MCF-7 cells. EpCAM silencing
was not observed in PEI alone or PEI-ScrApt-SiEp nano-
complex treatments. The EpCAM protein expression, in
PEI alone or PEI-ScrApt-SiEp (showed upregulation only
in WERI-Rb1) treated cells did not show significant
change compared to untreated cells which are in agree-
ment with mRNA levels (Figure 5B, 3rd and 5th lane). A
reduction in EpCAM protein expression was observed in
PEI-EpApt-SiEp nanocomplex and siRNA treated cells
Figure 4 Cell Uptake of the PEI nanocomplex by MCF-7 and WERI-Rb1 cells. The fabricated PEI complexes and free aptamer were added to
MCF-7 cells (upper panel A-E), WERI-Rb1 cells (lower panel A-E) and incubated for their uptake at 37°C for 4 h followed DAPI counterstaining and
microscopic evaluation. Images were taken at 40× using AxioObserver fluorescent microscope. Legend on the top of phase image represents the
aptamer or nanocomplex added to the respective panels.
Figure 3 Expression of EpCAM & binding of the complexes on cells. A. Histogram overlay plot showing the expression levels of EpCAM protein
in MCF-7 cells were evaluated using antibody based method and flow cytometry. B. Histogram overlay plot of MCF-7 cells bound to EpApt/EpDT3 or
ScrApt/ScrDT3. C. Histogram overlay plot of MCF-7 cells bound to aptamer alone or PEI-Apt-siRNA complexes. D. Histogram overlay of WERI-Rb1 cells.
Aptamer alone or complexes were added to cells and incubated for 2 h, washed & checked by flow cytometry. E. Flow cytometry analysis and histogram
overlay plot showing the cells blocked with EpCAM antibody before incubating with EpDT3-FI or with EpDT3-FI alone and unstained cells. F. Flow cytometry
analysis and histogram overlay plot of cells blocked with antibody followed by incubation with PEI-EpApt-SiEp.
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Figure 5 Expression of EpCAM post silencing using PEI Nanocomplexes. A. qPCR analysis, graph showing the fold change in the EpCAM
expression levels, calculated by normalizing with untreated controls and using GAPDH as internal control gene. qPCR was performed post
treatment with PEI alone or PEI-Apt-siRNA complexes or silencing using Lipo-siEp. B. Immunoblots were performed for EpCAM and beta-actin to
check the silencing efficiency at protein level using EpCAM C-10 primary antibody from Santa Cruz at 1:400 dilution, secondary anti- mouse IgG
HRP from Santacruz at 1:1000 dilution. C. Densitometry of the immunoblot normalized with tubulin-internal control and untreated control. D. Cell
proliferation was assessed by performing MTT assay. The graph represents the percentage cell proliferation after treatment with the aptamer
alone or PEI alone or PEI-Apt-siRNA complexes. Percentage cell proliferation was calculated considering untreated cells as controls in MCF-7
&WERI-Rb1 cell lines.
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the proteins levels were quantified by densitometry of
Western blots. A 35 and 33% reduction in EpCAM ex-
pression was observed using lipofectamine mediated
transfection of SiEp in MCF-7 and WERI-Rb1 cells, re-
spectively. Furthermore, 38 and 52% reduction in EpCAM
levels was obtained with PEI-EpApt-SiEp in MCF-7 and
WERI-Rb1 cells, respectively (Figure 5C). There was a
positive correlation between the mRNA and protein
expression levels in the control, PEI-ScrApt-siEp and
PEI-EpApt-SiEp group of MCF-7 and WERI-Rb1 cells
(R2 value 0.99 and 0.86) (Additional file 2: Figures S2B
& C). We performed MTT assay to evaluate the cellproliferation to determine if the changes in EpCAM
protein levels had effect on the cell viability. A significant
decrease in the cell viability was observed in the cells
treated with PEI-EpApt-SiEp nanocomplex compared to
siRNA alone (P value < 0.05) (Figure 5D). In MCF-7 and
WERI-Rb1 cells, transfection with the SiEp showed 50
and 52% inhibition, respectively whereas the PEI-EpApt-
SiEp showed higher inhibition(69% and 68% inhibition,
respectively) in these cell lines (P < 0.001). A negligible
effect on the cell proliferation was observed in the apta-
mer alone or PEI alone or PEI-ScrApt-SiEp nanocomplex
treated cells. One-way ANOVA analysis showed sig-
nificant difference (P <0.0005) between the subgroups.
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tween the SiEp treated group and PEI-EpApt-SiEp
group, unpaired student t-test was performed and
found to have significant difference (P < 0.005) in both
the cell lines.
Discussion and conclusions
There are challenges behind the targeted delivery of
siRNA specifically to cancer cells and nonviral carriers
such as PEI, poly(lactic-co-glycolic acid) (PLGA), lipo-
somes are found to be better delivery systems [30-32].
The PEI nanocomplex has good transfection efficiency
for the siRNA delivery purposes. The cytotoxicity of PEI
being an issue, can be managed by using optimal levels
that are non-toxic as well have uncompromised effi-
ciency to deliver siRNA/pDNA. Charge stabilization of
the PEI is found to be necessary to maintain uniform
size [33]. The size and charge of the PEI nanoparticles
synthesized in the present study are in agreement with
previous reports on PEI nanoparticle fabrications using
sgc-8c and PSMA, respectively [34,35]. PEI/pDNA poly-
plexes assembled with PTK7/sgc-8c aptamer showed
particle size ranging from 160–275 nm. In the PSMA
aptamer and siRNA chimera assembly on quantum dots
surrounded by PEI (QD-PEI), surface charge reportedly
drops down upon the siRNA and aptamer addition,
which was observed in our study too. A negative charge
was observed on the PEI nanocomplex in the presence
of siRNA and aptamer compared to the PEI nanocore
alone. The hydrodynamic size was higher compared to
the size of the particles observed by TEM due to the
fact that aptamer and siRNA present on the surface,
increased the electron dense nanocore size by 30 nm
(hydrodynamic size). The TEM gives the nanocore size
and not the surface aptamer and siRNA molecules
[36]. The initial influence of the serum proteins on
the nanocomplex binding to cells were managed by
adding the complex in serum free media, followed by
replenishment with serum containing media, to enhance
the uptake of the nanocomplex by the cell. The presence
of serum in general helps to prevent cytotoxicity of the
PEI by increasing membrane integrity of the cell but leads
to lower cellular uptake of the particles [37,38].
The scramble nanocomplex had minimal or no bind-
ing on cells that proves the specificity of the nanocom-
plex in this study. The increase in mean fluorescence
intensity (MFI) of cells bound with nanocomplex fabri-
cated with EpApt confirms that more than an aptamer
is engaged per PEI nanocomplex. Hence binding of
nanocomplex to a receptor compared to an aptamer
alone results in the increase in MFI. Blocking the
EpCAM receptor using a monoclonal antibody reduced
the binding of aptamer alone and PEI-EpApt-SiEp
nanocomplexes exhibiting lower MFI, confirming thereceptor specific binding. The observation that less
aptamer is required to saturate the cancer cells in the
PEI nanocomplex compared to the EpApt alone i.e.,
400 nM of aptamer required to show 90% cell binding
in MCF-7 cells compared to 200 nM required in PEI
nanocomplex, showed thereby, better performance/
affinity of the nanocomplex. This implies that we can
bring down the required concentration of aptamer by
preparing nanoformulation. Furthermore, the nano-
complex based formulation increases the bioavailability
and reactivity of the aptamer to the receptor. Other
group had similar observation while using quantum
dot-PEI-siRNA-aptamer targeted to PSMA in prostate
cancer [34]. The observed marginal binding not mediated
by the receptor mediated endocytosis, could be due to the
free positively charged PEI groups, which might access the
negatively charged cell membrane. Similar non specific
binding was observed in the earlier reports [25].
The PEI alone or scramble aptamer targeted complex
did not show any effect on the EpCAM gene expression
whereas the silencing efficiency of the EpCAM aptamer
targeted nanocomplex had reduced EpCAM expression.
The EpCAM silencing was considered as a read out for
the delivery of the siRNA inside cells, as the aptamer
was found to be internalized as observed by microscopy.
The targeted gene silencing was better than the conven-
tional lipofection. Other investigators had observed
gene silencing effect using PEI nanocomplex targeted
against PTK7 and PSMA [29,34]. The mechanism be-
hind the better silencing effect exerted by our nanocom-
plex is due to the guided delivery of EpCAM siRNA to
the EpCAM overexpressing cells. The downregulation
of EpCAM mRNA in both the EpCAM overexpressing
and moderately expressed cell population thus lead to
the cumulative effect. EpCAM antibody-gold nanopar-
ticle based targeting of siEp using PEI had 6 fold en-
hanced silencing of EpCAM gene expression than the
lipofectamine or untargeted siRNA delivery [28]. The
fold change observed in the current study is lesser than
the antibody mediated siRNA delivery, but the func-
tional activity of our nanocomplex is superior and tar-
geted by EpApt to induce cytotoxicity specifically on
EpCAM overexpressing cells. Thus the PEI nanocomplex
can be further expanded to the delivery of ribozymes
and DNAzyme. Similarly drugs such as doxorubicin
were delivered using PEI nanocomplexes [39]; these can
be made targeted by tagging aptamers on their surface.
In the present study, we fabricated a nanoformulation of
PEI with aptamer and siRNA and showed the efficient
targeting ability to the EpCAM positive cells. The tar-
geted nanoformulation had better gene silencing activity
than the conventional silencing mechanisms. This can
be further translated to in vivo system for therapeutic
purpose.
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Additional file 1: Supplementary materials and methods.
Additional file 2: Figure S1. Effect of media and serum on PEI
nanocomplexes. A. The hydrodynamic diameter of the PEI-Apt-siRNA
complexes prepared in medium with and without serum were measured
in zetasizer and ploted as histogram overlay plot against the percent number
distribution. B. Graphs showing the zeta potential of the complexes prepared
in medium with and without serum. Figure S2. EpCAM expression in
WERI-Rb1 cell line. A. The histogram overlay plot shows the expression
level of EpCAM by flow cytometry assay. The isotype control vs the
EpCAM expression reveals (blue) about 35% positive cells for the expression.
(Figure represented from earlier publication) [8]. The mRNA and protein
levels of EpCAM across the control, PEI-ScrApt-SiEp and PEI-EpApt-siRNA
were compared by fixing the protein levels in x-axis and mRNA levels in
y-Axis. The R2value is determined from the trend line drawn between
the samples. The equation is displayed on the left for both the cell lines
MCF-7 (B) and WERI-Rb1 (C).
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